Genes differentially expressed in prostate cancer

Because of the heterogeneity of prostate cancer knowledge about the genes involved in prostate carcinogenesis is still very limited. Previously, the use of novel high‐throughput technologies offered the possibility to investigate broad gene expression profiles and thus helped to improve understanding of the molecular basis of prostate disease. Many candidate genes have been identified so far which have a more or less strong effect on prostate cancer. This vast number of gene expression changes show that it is unlikely that only one gene promotes prostate cancer. Conversely, it seems more likely that a broad network of molecular changes is involved in the complex cascade of events which lead to tumour formation and progression, respectively. A few of these novel molecular targets are currently under clinical evaluation. This paper gives an overview of several interesting candidate genes which may be useful as improved biomarkers for diagnosis or as targets for developing novel treatment methods.

[1]  A. Schned,et al.  Phase I Pilot Trial of the Bispecific Antibody MDXH210 (anti-Fc&ggr;RI X anti–HER-2/neu) in Patients Whose Prostate Cancer Overexpresses HER-2/neu , 2001, Journal of immunotherapy.

[2]  K. Meehan,et al.  Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer , 2002, The Prostate.

[3]  K. Porkka,et al.  Detection of differentially expressed genes in prostate cancer by combining suppression subtractive hybridization and cDNA library array , 2001, The Journal of pathology.

[4]  H. Klocker,et al.  Prostate cancer screening in Tyrol, Austria: experience and results. , 2000, European urology.

[5]  J. Brooks,et al.  CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[6]  Arul M Chinnaiyan,et al.  Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. , 2003, Journal of the National Cancer Institute.

[7]  J. Epstein,et al.  Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. , 2003, The Journal of urology.

[8]  G. Hortobagyi,et al.  Growth factor receptors in breast cancer: potential for therapeutic intervention. , 2003, The oncologist.

[9]  Michael J. Wilson,et al.  Expression of matrix metalloproteinase‐2 and ‐9 and their inhibitors, tissue inhibitor of metalloproteinase‐1 and ‐2, in primary cultures of human prostatic stromal and epithelial cells * † , 2002, Journal of cellular physiology.

[10]  D. Mercola,et al.  Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo , 2003, Oncogene.

[11]  Biaoyang Lin,et al.  The program of androgen-responsive genes in neoplastic prostate epithelium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  T. Stamey,et al.  Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. , 2001, The Journal of urology.

[13]  A. Menssen,et al.  Characterization of epithelial senescence by serial analysis of gene expression: identification of genes potentially involved in prostate cancer. , 2002, Cancer research.

[14]  M. Gleave,et al.  A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  H. Klocker,et al.  Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells , 2003, Molecular carcinogenesis.

[16]  L. Hood,et al.  Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. , 1998, Cancer research.

[17]  L. Klotz,et al.  Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. , 1998, Cancer research.

[18]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[19]  W. Powell,et al.  Suppression of prostate carcinoma cell invasion by expression of antisense L-plastin gene. , 1999, The American journal of pathology.

[20]  J. Schiller New directions for ZD1839 in the treatment of solid tumors. , 2003, Seminars in oncology.

[21]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[22]  Spyro Mousses,et al.  Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. , 2002, Cancer research.

[23]  L. Kiemeney,et al.  DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer , 2003 .

[24]  H. Bonkhoff,et al.  Differential expression of the estrogen receptor beta (ERβ) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma , 2003, The Prostate.

[25]  H. Miyake,et al.  Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  T. Roskams,et al.  Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer , 2002, International journal of cancer.

[27]  J. Moul,et al.  Quantitative expression profile of androgen‐regulated genes in prostate cancer cells and identification of prostate‐specific genes , 2001, International journal of cancer.

[28]  A. Zietman,et al.  Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate cancer-results from a pilot study. , 2000, Urology.

[29]  A. Wakeling,et al.  Growth factors and their receptors: new targets for prostate cancer therapy. , 2001, Urology.

[30]  L. Bubendorf,et al.  Expression of NKX3.1 in normal and malignant tissues , 2003, The Prostate.

[31]  B. Gumbiner,et al.  Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin , 2003, The Journal of cell biology.

[32]  A. Belldegrun,et al.  Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. , 2003, Cancer research.

[33]  M. Jordá,et al.  Her2 expression in prostatic cancer: a comparison with mammary carcinoma. , 2002, The Journal of urology.

[34]  J. Welsh,et al.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.

[35]  S. Egawa,et al.  Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. , 2002, Anticancer research.

[36]  J. Swinnen,et al.  Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. , 2003, Biochemical and biophysical research communications.

[37]  J. Richie,et al.  Expression of cell cycle-regulated proteins in prostate cancer. , 1996, Cancer research.

[38]  E. Riboli,et al.  Ratios of IGF-I, IGF binding protein-3, and prostate-specific antigen in prostate cancer detection. , 2001, The Journal of clinical endocrinology and metabolism.

[39]  K. Pienta,et al.  E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. , 2001, Human pathology.

[40]  M. Gleave,et al.  Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. , 2001, Urology.

[41]  I. Mellinghoff,et al.  Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. , 2002, Cancer research.

[42]  M. Gleave,et al.  Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. , 2003, Cancer research.

[43]  H. Frierson,et al.  p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. , 1997, The Journal of urology.

[44]  E Mahlamäki,et al.  Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. , 1999, Journal of the National Cancer Institute.

[45]  M. Bittner,et al.  Expression profiling using cDNA microarrays , 1999, Nature Genetics.

[46]  H. Miyake,et al.  Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. , 2000, Cancer research.

[47]  H. Kanetake,et al.  Serum insulin‐like growth factor binding protein‐3/prostate‐specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer , 2003, The Prostate.

[48]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[49]  W. Isaacs,et al.  DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.

[50]  H. Klocker,et al.  Molecular Biology of the Androgen Receptor: From Molecular Understanding to the Clinic , 2001, European Urology.

[51]  E. Small,et al.  Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. , 2001, Seminars in oncology.

[52]  R. Cheng,et al.  Age-Associated Changes in Histology and Gene-Expression Profile in the Rat Ventral Prostate , 2003, Laboratory Investigation.

[53]  R. Cardiff,et al.  Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Zhou Wang,et al.  Farnesyl diphosphate synthase is abundantly expressed and regulated by androgen in rat prostatic epithelial cells , 2001, The Journal of Steroid Biochemistry and Molecular Biology.